Skip to content

News Category: Health & Medical

Suvoda 2022 Clinical Trials Surge 20% as it Expands Offerings to Include eConsent and eCOA

By asianet

— Company achieves Top Performer status in ISR IRT Benchmark Survey Suvoda LLC ( https://c212.net/c/link/?t=0&l=en&o=3756407-1&h=3282413622&u=https%3A%2F%2Fwww.suvoda.com%2F%3Futm_medium%3Dpress-release%26utm_source%3Dpress-release%26utm_campaign%3Dmomentum-release-2023%26utm_content%3Dpress-release-momentum-2023-01&a=Suvoda+LLC ) , a global clinical trial technology company that specializes in complex studies in therapeutic areas like oncology, central nervous system (CNS), and rare disease, surpassed 1,000 clinical trials in 2022 as study deployments surged nearly 20%, a strong indicator … Continued

Sai Life Sciences opens new High-Potency API Manufacturing facility at its Bidar Campus

By asianet

– Designed and validated to handle high potent molecules less than 1 microgram/m3 containment – First commercial production batch has commenced Sai Life Sciences, one of India’s fastest growing Contract Research [ https://www.sailife.com/?utm_source=pr&utm_medium=web&utm_campaign=hpapi-bidar ] , Development & Manufacturing Organizations [ https://www.sailife.com/?utm_source=pr&utm_medium=web&utm_campaign=hpapi-bidar ] (CRO-CDMO), today announced the opening of a new High-Potency API (HPAPI) manufacturing facility … Continued

OPHTECS Global Team Welcomes Dr. Schnider, One of Most Influential Women in Optical Industry and One of World’s Most Prominent Contact Lens Researchers and Educators

By asianet

– Enforcing Company’s R&D Efforts for New Lens Care Products and Global Professional Relation Activities – OPHTECS Corporation (hereinafter referred to as OPHTECS), a Kobe-based company which researches, develops, produces and markets contact lens care products, has signed a new advisory contract with Dr. Cristina M. Schnider as the company’s Senior Director, Global Medical Affairs. … Continued

TPIsoftware’s AI-Powered SysTalk.Chat to Elevate Chang Gung Memorial Hospital’s Customer Services

By asianet

Taking the trophy as the one of the best products in Taiwan at Taiwan Excellence Awards 2023, TPIsoftware’s SysTalk.Chat(https://www.tpisoftware.com/en/products/systalk-chat), the conversational AI chatbot, has reached new heights in driving smart healthcare with AI-powered customer services. By adopting SysTalk.Chat, Chang Gung Memorial Hospital (CGMH), the largest hospital in Taiwan, has become the first medical institution in … Continued

DEBIOPHARM APPLIES EXTENDED-RELEASE FORMULATION EXPERTISE TO REDUCE TREATMENT FREQUENCY BURDEN FOR ACROMEGALY & GEP-NET PATIENTS

By asianet

–  Acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare diseases that require life-long chronic treatment. Monthly somatostatin analog (SSA) injections are the standard of care as first-line medical treatment. –  Debiopharm is developing Debio 4126, a novel 3-month extended-release octreotide formulation, to optimize acromegaly and GEP-NET patient care by reducing injection frequency, which translates into … Continued

Mars Petcare and the Broad Institute create open-access database of dog and cat genomes to advance preventive pet care

By asianet

– The genome database will power ongoing scientific efforts worldwide and help advance individualized pet health care – Insights from this partnership will feed into the MARS PETCARE BIOBANK(TM), a longitudinal study to understand pet health and disease, transforming pet care for future generations of dogs and cats – Mars Petcare Science & Diagnostics President, … Continued

MedAlliance SELUTION SLR is the first DEB to receive coronary de novo IDE approval, its fourth FDA IDE DEB Approval

By asianet

SELUTION SLR(TM), MedAlliance’s novel sirolimus-eluting balloon, has received conditional FDA Investigational Device Exemption (IDE) approval to initiate its pivotal clinical trial for the treatment of coronary de novo lesions. This comes less than eight months after the company received its first IDE approval for SELUTION SLR in the treatment of below-the-knee (BTK) indications; as well … Continued

Ajinomoto and Exelixis Enter Into a License Agreement to Discover and Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer

By asianet

Ajinomoto Co., Inc. (“Ajinomoto Co.”) today announced a license agreement with Exelixis, Inc. (“Exelixis”) to incorporate AJICAP(R), Ajinomoto Co.’s proprietary site-specific bioconjugation and linker technologies, in the development of certain of Exelixis’ antibody-drug conjugate (ADC) programs. Logo – https://mma.prnewswire.com/media/751177/Aji_BioPharma_Logo.jpg Exelixis is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and … Continued

Renexxion Announces Opening of Investigational New Drug (IND) Application for Naronapride for the Treatment of Gastrointestinal Dysmotility in Cystic Fibrosis Patients

By asianet

Renexxion Ireland Limited (Renexxion), a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need in gastrointestinal (“GI”) disorders, is pleased to announce opening of the Investigational New Drug (IND) application with the U.S Food and Drug Administration (FDA) for naronapride for the treatment of GI motility disorders in patients with … Continued